Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT06662383·Phase 3·INTERVENTIONAL

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

RetatrutideTirzepatideGlucagonWeight lossActive, not recruiting

Status

Active, not recruiting

Phase

Phase 3

Enrollment

800

Locations

65

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.

Interventions

Treatment arms and agents.

DRUG

Retatrutide

Administered SC

DRUG

Tirzepatide

Administered SC

Timeline

From registration to results.

  1. First posted

    Oct 28, 2024

  2. Study start

    Nov 1, 2024

  3. Primary completion

    Nov 2026

  4. Study completion

    Dec 2026

  5. Results posted

    Not reported

  6. Registry updated

    Jul 20, 2026

Outcomes

What the study measures.

Primary outcomes

Percent Change from Baseline in Body Weight

Time frame · Baseline, Week 80

Secondary outcomes

Change from Baseline in Body Mass Index (BMI)

Time frame · Baseline, Week 80

Change from Baseline in Waist Circumference

Time frame · Baseline, Week 80

Percent Change from Baseline in Total Cholesterol

Time frame · Baseline, Week 80

Percent Change from Baseline in Triglycerides

Time frame · Baseline, Week 80

Change from Baseline in Systolic Blood Pressure (SBP)

Time frame · Baseline, Week 80

Change from Baseline in Diastolic Blood Pressure (DBP)

Time frame · Baseline, Week 80

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame · Baseline, Week 80

Percent Change from Baseline in Fasting Insulin

Time frame · Baseline, Week 80

Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

Time frame · Baseline, Week 80

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight. Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening. * Have a prior or planned surgical treatment for obesity. * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity. * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2). * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * coronary revascularization * hospitalization for unstable angina, or * hospitalization due to congestive heart failure. * Have New York Heart Association Functional Classification Class IV congestive heart failure. * Have a history of chronic or acute pancreatitis.

Study locations

65 registered sites.

Argentina · Germany · Poland · Puerto Rico · United States. Showing up to 24 locations stored in the fast local snapshot.

Medical Advancement Centers of Arizona

Tempe, Arizona, United States

Mary & Dick Allen Diabetes Center

Newport Beach, California, United States

Artemis Institute for Clinical Research

San Diego, California, United States

Encompass Clinical Research

Spring Valley, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Lynn Institute of Denver

Aurora, Colorado, United States

Bridgeport Hospital

Bridgeport, Connecticut, United States

Yale University School of Medicine

New Haven, Connecticut, United States

Encore Medical Research

Hollywood, Florida, United States

Suncoast Research Group

Miami, Florida, United States

Onhealth Research Center

Miami, Florida, United States

Precision Clinical Research

Sunrise, Florida, United States

Einstein Clinical Research

Vero Beach, Florida, United States

ClinCept Clinical Research - MH

Columbus, Georgia, United States

Northeast Georgia Medical Center

Gainesville, Georgia, United States

Pivotal Research Solutions

Stonecrest, Georgia, United States

East-West Medical Research Institute

Honolulu, Hawaii, United States

Northwestern University

Chicago, Illinois, United States

Integrated Clinical Trial Services, Inc.

West Des Moines, Iowa, United States

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Great Lakes Research Group, Inc.

Bay City, Michigan, United States

Great Lakes Research Institute

Southfield, Michigan, United States

StudyMetrix Research

City of Saint Peters, Missouri, United States

Las Vegas Endocrinology

Henderson, Nevada, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Retatrutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsRetatrutide trial dashboard →DatabaseRetatrutide database entry →ResearchRetatrutide research guide →MarketRetatrutide comparison →TrialsTirzepatide trial dashboard →DatabaseTirzepatide database entry →ResearchTirzepatide research guide →TrialsGlucagon trial dashboard →DatabaseGlucagon database entry →ResearchGlucagon research guide →Research vendor recordAscension Peptides →Research vendor recordNura Peptide →Research vendor recordEZ Peptides →Research vendor recordNOVA Labs →